JP Morgan Chase
ACXP icon

JP Morgan Chase’s Acurx Pharmaceuticals ACXP Stock Holding History

JP Morgan Chase’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$11 – 7028
2025
Q1 		$11 Buy
+1
New +$13 ﹤0.01% 7180
2024
Q1 		– Sell
-26
Closed -$1.96K – 7360
2023
Q4 		$1.96K Buy
+26
New +$1.96K ﹤0.01% 6723

Other funds holding ACXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OBGC
O'Brien Greene & Co Media, Pennsylvania $353M AUM 30.94% 1-Year Est. Return

JP Morgan Chase's ACXP Position: Q2 2025 in Review

JP Morgan Chase sold out of Acurx Pharmaceuticals (ACXP) in Q2 2025, closing a stake of 1 share — an estimated $11 sold.

JP Morgan Chase first reported a position in ACXP in Q4 2023 and held it in 2 quarters. The position peaked at $1.96K in Q4 2023. 32 funds tracked by Wall St. Rank hold ACXP as of Q2 2025.

  • JP Morgan Chase reported no remaining Acurx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1 Acurx Pharmaceuticals share in Q2 2025, an estimated $11.
  • JP Morgan Chase first reported a position in Acurx Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • JP Morgan Chase's Acurx Pharmaceuticals position peaked at $1.96K in Q4 2023.
  • 32 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.